Compared with our own and Frangolias’ studies, Amati et al. [42] found lower antitrypsin levels in CF patients with wild-type antitrypsin, but this could be explained by differences in CFTR gene mutations, levels of microbial colonization, antimicrobial treatments and medications. This evidence concerns the gene CFTR and cystic fibrosis.